Physician profile
Darice Yang
NPI 1427255454
$7,211.97
in general payments reported to CMS, 2019-2025
27 companies · $2,751 in 2025
The $2,751 reported for 2025 was more than what 75% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,646 · 2020: $115 · 2021: $192 · 2022: $227 · 2023: $652 · 2024: $1,629 · 2025: $2,751.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,024 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,023.73 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,927.38 | 2019-2025 | Enbrel, Otezla, Otezla |
| Abbvie INC. | $1,838.60 | 2019-2025 | Rinvoq |
| Ucb, INC. | $676.54 | 2019-2025 | Bimzelx |
| Novartis Pharmaceuticals Corporation | $652.80 | 2019-2025 | |
| Glaxosmithkline, LLC. | $359.05 | 2019-2025 | Benlysta |
| Genzyme Corporation | $238.43 | 2019-2025 | |
| Horizon Therapeutics Plc | $224.56 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $188.77 | 2024-2025 | Strensiq |
| Janssen Biotech, INC. | $147.95 | 2019-2025 | Tremfya |
| Lilly USA, LLC | $145.47 | 2019-2025 | Zepbound, Taltz, Jardiance |
| Genentech USA, INC. | $106.70 | 2019-2024 | Actemra |
| Radius Health, INC. | $106.66 | 2019-2024 | Tymlos |
| Astrazeneca Pharmaceuticals Lp | $80.05 | 2023-2025 | Saphnelo |
| Medexus Pharma, INC. | $77.32 | 2019 | |
| Merck Sharp & Dohme LLC | $74.23 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $56.91 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Abbott Laboratories | $50.73 | 2019-2025 | Freestyle Libre 3 |
| Fresenius Kabi USA, LLC | $35.81 | 2024-2025 | Idacio, Adalimumab-Aacf |
| Pfizer INC. | $33.87 | 2019 | |
| Aurinia Pharma U.S., INC. | $33.08 | 2023-2024 | Lupkynis |
| Neurocrine Biosciences, INC. | $30.31 | 2025 | |
| Ascendis Pharma Endocrinology INC | $26.35 | 2025 | Skytrofa |
| Becton, Dickinson and Company | $25.59 | 2019 | |
| Kyowa Kirin, INC. | $20.91 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $20.89 | 2021 | |
| Ascensia Diabetes Care US INC. | $17.13 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $15.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darice Yang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.